InfiniTrak Announces 150th Chain With More Than 50% Share of Pharmacy Chains

TOLEDO, Ohio, July 16, 2026 /PRNewswire/ — InfiniTrak is the industry-leading provider of Drug Supply Chain Security Act compliance technology; starting with just two chains in 2020, InfiniTrak has grown to 150 chains today. The growth reflects rising demand for DSCSA software integrated with pharmacy systems.

“Reaching our 150th pharmacy chain, after starting with just two, proves InfiniTrak’s dominance within the pharmacy chain space. Over the past six years, InfiniTrak has experienced tremendous growth. There are several key reasons more chains have switched to InfiniTrak than all of our competitors combined. We have continued to enhance and improve our solution, which has been critical to our success. Our expertise in technology and automation, along with the knowledge of our incredible team in both DSCSA and pharmacy operations, has proven particularly beneficial. This unmatched combination of technology and people is what sets us apart,” said Mark Tate, Co-Founder and Chief Compliance Officer of InfiniTrak.

InfiniTrak’s automated DSCSA compliance platform integrates with more than 30 industry-leading pharmacy systems, including several exclusive integrations. This continued trust has reinforced InfiniTrak’s position as a leading DSCSA provider for large retail chains. 2026 marks the fifth consecutive year of record customer growth for InfiniTrak with thousands of pharmacies that have already switched from other DSCSA providers.

As DSCSA requirements evolve and FDA enforcement increases, InfiniTrak transforms complex DSCSA requirements into a connected, interoperable platform that gives pharmacies greater control over traceability, exceptions, and compliance activity, keeping them audit-ready 24/7.

Justin Hammerling, Senior Vice President of Business Development at InfiniTrak said “Our technology provides functionality beyond compliance. With our advanced integrations and AI-managed workflows, InfiniTrak supports retail chains managing compliance across thousands of locations as well as independent pharmacies establishing DSCSA processes for the first time. Most notably, the last four large chains that signed with InfiniTrak came from our main competitors. There isn’t a better way to demonstrate that we are the #1 solution for large chains. As the pharmaceutical supply chain advances, InfiniTrak will continue setting the standard for integrated DSCSA technology”.

About InfiniTrak

InfiniTrak was an early innovator of track-and-trace technology. Built specifically with the needs of the end user in mind, the company offers an intuitive, user-friendly DSCSA solution that automates operations and integrates seamlessly into existing pharmacy workflows.

InfiniTrak accelerates the path to compliance by providing tools that address all DSCSA requirements. In addition to its comprehensive compliance features, InfiniTrak has robust integration capabilities. To date, InfiniTrak integrates with more than 30 leading pharmacy systems across the United States, Guam, and Puerto Rico.

The company is primarily the preferred and/or exclusive DSCSA solution for industry leaders, including PioneerRx, Pharmacy One by Liberty Software, BestRx, PrimeRx, FrameworkLTC by SoftWriters, EnterpriseRx by McKesson, DataScan, SRS, and WesCom, among many others.

InfiniTrak has also been increasing its market share in the wholesale industry. Over the past year alone, it has added 32 wholesalers seeking affordable, comprehensive DSCSA compliance supported by advanced technology.

InfiniTrak is headquartered in Toledo, Ohio, with technology offices in Northern Virginia. For more information about InfiniTrak visit: https://infinitrak.us/.

Media Contact
Justin Hammerling
Senior Vice President of Business Development at InfiniTrak
justin@infinitrak.us
(419)297-2920

View original content to download multimedia:https://www.prnewswire.com/news-releases/infinitrak-dominates-retail-pharmacy-chain-space-302827103.html

SOURCE InfiniTrak

Fans worldwide can watch the Mainstage and Freedom Stage live across both festival weekends

PROVIDENCIALES, Turks and Caicos Islands, July 16, 2026 /PRNewswire/ — KuCoin, a leading global crypto platform built on trust, today announced that the official livestream of Tomorrowland Belgium 2026 will be available directly on the KuCoin App, giving audiences worldwide access to live performances from one of the world’s most iconic electronic music festivals.

As Tomorrowland’s Official Exclusive Crypto Exchange and Crypto Payments Partner, KuCoin will stream performances from both the Mainstage and Freedom Stage across all six festival days on July 17–19 and July 24–26. The livestream will feature some of the biggest names in electronic music, including David Guetta, Martin Garrix, Calvin Harris, Hardwell, Armin van Buuren, Alok, Sebastian Ingrosso, The Chainsmokers, and many more.

Users can access the official livestream through the dedicated Tomorrowland page on the KuCoin App.

The livestream schedule is as follows, with all times listed in UTC:

July 17: 14:00–01:00July 18: 14:00–01:00July 19: 14:00–00:00July 24: 14:00–01:00July 25: 14:00–01:00July 26: 14:00–00:00

“Tomorrowland brings people together through music, creativity and shared experiences,” said BC Wong, CEO of KuCoin. “By bringing the official livestream to the KuCoin App, we are making that experience accessible to our global community, wherever they are. This is another meaningful step in our partnership and a reflection of how trusted technology can create stronger connections between people and culture.”

The livestream is part of KuCoin’s multi-year partnership with Tomorrowland, which also includes the debut of the Celestia Stage, the return of the KuCoin Guardians, and special activations celebrating KuCoin’s ninth anniversary on July 24. Together, these experiences reflect the shared vision of KuCoin and Tomorrowland to bring people together through music, innovation and meaningful connections.

By bringing the official Tomorrowland Belgium 2026 livestream to the KuCoin App, KuCoin is making one of the world’s most iconic music festivals more accessible to its global community. Whether attending the festival in person or watching from anywhere in the world, fans can come together to experience the music, creativity and energy that define Tomorrowland.

About KuCoin

Founded in 2017, KuCoin is a leading global crypto platform built on trust and security, serving over 40 million users across 200+ countries and regions. Known for its reliability and user-first approach, the platform combines advanced technology, deep liquidity, and strong security safeguards to deliver a seamless trading experience. KuCoin provides access to 1,500+ digital assets through a broad product suite and remains committed to building transparent, compliant, and user-centric digital asset infrastructure for the future of finance, backed by SOC 2 Type II, ISO/IEC 27001:2022, and ISO/IEC 27701:2019 Certifications. In recent years, we have built a strong global compliance foundation, marked by key milestones including AUSTRAC registration in Australia, a MiCA license in Europe, and regulatory progress in other markets.

Learn more at www.kucoin.com.

About Tomorrowland

Founded 20 years ago by Belgian brothers Manu and Michiel Beers, Tomorrowland remains a family-owned business driven by a creative and passionate team. Over the years, Tomorrowland has evolved into a global entertainment brand.

The WEAREONE.world group consists of several business units, including Festival & Events, Music, Experiences, Leisure, Products and Fiction. Today, more than 350 team members create magic from the company’s headquarters in Antwerp, Belgium, as well as local offices in Brazil, France, Ibiza and Thailand.

Known for bringing people together through music, creativity and storytelling, Tomorrowland has become one of the world’s most recognized and influential festival brands, inspiring millions through unforgettable experiences and a shared vision of connection.

View original content to download multimedia:https://www.prnewswire.com/news-releases/kucoin-brings-the-official-tomorrowland-belgium-2026-livestream-to-the-kucoin-app-302826303.html

SOURCE KuCoin

– FDA 510(k) Clearance (K253390) Validates AI-Based Classification of OSA, CSA, and MSA
– Subtype-Specific Respiratory Event Analysis Improves Diagnostic Precision and Supports Next-Generation Digital Biomarker Development
– Advanced AI Analysis Using Multi-Channel Physiological Signals, with Additional FDA 510(k) Clearances Planned for Future Releases

BOSTON, July 16, 2026 /PRNewswire/ — HoneyNaps, an AI-based sleep medicine company, today announced that SOMNUM V3.0, its AI diagnosis software for polysomnography (PSG) analysis, has received U.S. Food and Drug Administration (FDA) clearance under clearance number K253390.

SOMNUM is clinical decision support software designed to assist medical professionals in analyzing PSG data, including sleep staging and respiratory event detection. HoneyNaps previously received FDA clearance for SOMNUM V1.1.2, and the latest clearance expands the software’s capabilities for automated analysis of sleep-disordered breathing (SDB).

SOMNUM V3.0 automatically detects apnea and hypopnea events and classifies apnea into Obstructive Sleep Apnea (OSA), Central Sleep Apnea (CSA), and Mixed Sleep Apnea (MSA) using AI algorithms. Compared with conventional approaches that primarily assess SDB using composite indices, the software provides event-level classification intended to support more detailed clinical scoring.

According to validation results submitted as part of the FDA clearance process, the algorithms achieved Overall Percent Agreement (OPA) of more than 97% across respiratory event categories, supporting the software’s performance in automated event detection and classification.

By analyzing subtle physiological patterns from multi-channel biosignals, SOMNUM V3.0 is designed to distinguish different apnea subtypes that may be challenging to differentiate through manual scoring alone. HoneyNaps believes this capability may support more accurate assessment of sleep-disordered breathing severity and assist clinicians in treatment planning.

The company is also developing next-generation AI technologies and digital biomarkers, including Hypoxic Burden (HB), Arousal Burden (AB), and Ventilatory Burden (VB), to enable more comprehensive evaluation of disease severity and health risks associated with sleep apnea. HoneyNaps plans to pursue additional FDA 510(k) clearances for future SOMNUM versions incorporating these capabilities.

Sean Ha (Tae Kyoung Ha), President of HoneyNaps USA, stated, “The FDA 510(k) clearance for SOMNUM V3.0 represents regulatory validation of our AI algorithm’s clinical performance in automatically detecting and differentiating OSA, CSA, and MSA. We remain focused on advancing AI-driven sleep diagnostics through continued innovation in automated analysis and next-generation digital biomarkers.”

For further information, please contact:
HoneyNaps USA, Inc.
Christine Kwon / Managing Director
Email: sleep@honeynaps.com
Address: 14th Floor, One Broadway, Cambridge, MA 02142, USA
Website: www.honeynaps.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/honeynaps-receives-us-fda-510k-clearance-for-somnum-v3-0-for-ai-based-sleep-disordered-breathing-analysis-302827031.html

SOURCE HoneyNaps